Published in Medical Letter on the CDC and FDA, June 13th, 2010
Dr. Skovronsky will provide attendees with an update on Phase III clinical trials and commercialization efforts for Avid's amyloid imaging compound Florbetapir 18F-AV-45 (AV-45). This tracer is the most advanced compound of its type in development for imaging amyloid plaque in the brain associated with Alzheimer's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.